Recent developments include the termination of a business combination agreement with United Hydrogen, which led to a share price decline, and insider share sales by a significant shareholder.

• A business combination agreement with United Hydrogen was terminated, causing a significant decline in Aimei Health's share price [N1].
• An insider holding 10% of shares sold 150,000 shares in February 2025 [N2].

The company’s experienced management team and prior interest income from Trust Account funds provide a foundation for pursuing a business combination. Successful identification and completion of a business combination could enable operational activities and revenue generation. The company’s remediation plans for internal control weaknesses may improve governance and financial reporting reliability.

The company has not generated operating revenue and faces significant liquidity constraints, with a current ratio of 0.01 as of June 30, 2026. The termination of the business combination agreement with United Hydrogen introduces uncertainty about future strategic direction. Material weaknesses in internal controls pose risks to financial reporting and operational oversight. The company’s ability to consummate a business combination within required timelines is uncertain, raising going concern considerations.

As a SPAC without operating history or revenue, Aimei Health Technology Co., Ltd. does not currently possess competitive advantages or a moat. Its value proposition depends on successfully completing a business combination and subsequent operational execution, which remains uncertain.

• Liquidity Risk: The company has a working capital deficit and a very low current ratio, indicating potential challenges in meeting short-term obligations [S1][S2].
• Business Combination Uncertainty: Failure to complete a business combination within prescribed timelines may require ceasing operations and liquidating, raising going concern issues [S1].
• Internal Control Weaknesses: Material weaknesses in internal controls over financial reporting due to inadequate segregation of duties and insufficient policies increase risk of errors or misstatements [S1].
• Market Reaction to Business Combination Termination: The termination of the business combination agreement with United Hydrogen caused a significant share price decline, reflecting market uncertainty [N1].
• Insider Share Sales: Insider sales, such as the 10% owner selling 150,000 shares, may signal insider views on company prospects [N2].

• Aimei Health Technology Co., Ltd. is a special purpose acquisition company (SPAC) that has not engaged in operations or generated revenue to date, focusing on identifying and completing a business combination [S1].
• The company generated net income in 2024 and 2025 primarily from interest income on cash held in a Trust Account, offset by administrative and operational expenses [S1].
• As of December 31, 2025, the company had a working capital deficit of approximately $3.37 million and held $12.1 million in its Trust Account [S1].
• The company’s liquidity as of June 30, 2026, shows current assets of $43,966 and current liabilities of $3,838,684, resulting in a current ratio of 0.01, indicating significant liquidity constraints [S2].
• The company reported a net loss of $83,144 for the quarter ended June 30, 2026 [S2].
• The company’s internal controls over financial reporting were assessed as not effective as of December 31, 2025, due to material weaknesses related to segregation of duties and insufficient policies, with remediation plans underway [S1].
• The company’s executive team includes CEO Junheng Xie and CFO Heung Ming Wong, both with relevant experience in health technology and finance [S1].
• A business combination agreement with United Hydrogen was terminated, which caused a significant share price decline [N1].
• An insider holding 10% of shares sold 150,000 shares in February 2025 [N2].